Contact this trialFirst, we need to learn more about you.
Kinase Inhibitor
Encorafenib/Binimetinib/Nivolumab vs Ipilimumab/Nivolumab for Melanoma
Recruiting1 awardPhase 2
Fairhope, Alabama
This trial compares the effect of two different drug combinations in treating patients with melanoma that has spread to the brain. One combination is encorafenib and binimetinib, which may stop the growth of tumor cells. The other combination is ipilimumab and nivolumab, which are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread. This trial aims to find out which approach is more effective in shrinking and controlling brain metastases from melanoma.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service